Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q3 2023 Earnings Conference Call November 8, 2023 8:00 AM ET Company Participants Carrie Siragusa - VP of Marketing Lonnel Coats - CEO Tom Garner - Chief Commercial Officer Craig Granowitz - Chief Medical Officer Jeffrey Wade - President and CFO Conference Call Participants Andrew Tsai - Jefferies Joseph Stringer - Needham & Company Operator Good day and welcome to the Lexicon Pharmaceuticals' Third Quarter 2023 Financial Results Conference Call. Today all partici ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _____________ to _____________ Commission File Number: 000-30111 Lexicon Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) (State or ...

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q2 2023 Earnings Conference Call August 3, 2023 5:00 PM ET Company Participants Carrie Siragusa - Vice President of Marketing Lonnel Coats - Chief Executive Officer Jeffrey Wade - President and Chief Financial Officer Craig Granowitz - Chief Medical Officer Conference Call Participants Carly Kenselaar - Citigroup Inc. Andrew Tsai - Jefferies Group LLC Operator Good day, and welcome to the Lexicon Pharmaceuticals Second Quarter 2023 Financial Results Conference Cal ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _____________ to _____________ Commission File Number: 000-30111 Lexicon Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) (State o ...

Financial Data and Key Metrics - The company ended Q1 2023 with $105.9 million in cash and investments, providing sufficient resources for commercial preparations and R&D investments [42] - Selling, general, and administrative expenses increased to $19.5 million in Q1 2023, up from $8.5 million in Q1 2022, primarily due to headcount growth and commercial launch preparations for sotagliflozin [43] - Net loss for Q1 2023 was $23.5 million, or $0.16 per share, compared to the same period in 2022 [51] Business Line Data and Key Metrics - Sotagliflozin, a dual SGLT1 and 2 inhibitor for heart failure, is on track for its PDUFA target date of May 27th, with no substantial review issues identified by the FDA [5] - LX9211, an AAK1 inhibitor for neuropathic pain, has shown consistent results across two Phase 2 studies, with FDA feedback expected in Q2 2023 for late-stage development plans [4][49] - The neuropathic pain market is projected to grow by over 13% worldwide between 2020 and 2026, reaching $13.2 billion, presenting a significant opportunity for LX9211 [45] Market Data and Key Metrics - Heart failure is a multi-billion dollar market with substantial growth potential, driven by increasing disease prevalence and new treatment guidelines recommending SGLT inhibitors [12] - The annual cost of heart failure is expected to rise to nearly $70 billion by 2030, with 80% of costs due to hospitalizations, highlighting the need for better treatment options [8] - Currently, fewer than 10% of heart failure patients are discharged with a prescription for an SGLT inhibitor, indicating a significant market opportunity for sotagliflozin [21] Company Strategy and Industry Competition - The company is focusing on the transition of care patient population for sotagliflozin, leveraging its unique data on reducing hospital readmissions and cardiovascular mortality [55][65] - Updated heart failure treatment guidelines and the early adoption curve for SGLT inhibitors provide a strong tailwind for sotagliflozin's commercial launch [36][98] - LX9211 is being advanced as a potential new mechanism for treating neuropathic pain, with plans to optimize dosing regimens and pursue late-stage development [49][72] Management Commentary on Operating Environment and Future Outlook - Management is confident in the commercial launch preparations for sotagliflozin, with infrastructure and resources in place for a successful launch in Q2 2023 [32][75] - The company is actively engaging with payers, hospital systems, and government institutions to ensure broad access and formulary coverage for sotagliflozin [6][65] - Feedback from the FDA on LX9211's development path is expected in Q2 2023, with plans to advance the program into late-stage development [49][62] Other Important Information - The company has secured a loan facility with Oxford Finance, providing up to $100 million in additional borrowing capacity, including $75 million available upon sotagliflozin approval [73] - Sotagliflozin has demonstrated a 33% reduction in the composite endpoint of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits, with a need to treat only four patients for one year to avoid one event [13] - LX9211 has shown consistent efficacy across two Phase 2 studies, with no drug-related serious adverse events or deaths reported [47][71] Q&A Session Summary Question: What should investors focus on regarding the potential label for sotagliflozin? - The company expects a broad label for sotagliflozin, covering heart failure across all left ventricular ejection fractions, including HFpEF [53][77] Question: What are the key drivers for sales acceleration in 2023 and 2024? - The company will focus on penetrating integrated delivery networks (IDNs) and securing Medicare coverage in 2023, with net sales growth expected in 2024 [79] Question: What is the status of LX9211's development and potential partnerships? - The company is advancing LX9211 into late-stage development for diabetic peripheral neuropathic pain (DPN) and is open to partnerships but will not delay development [62][95] Question: How receptive are payers and hospital systems to sotagliflozin's value proposition? - Receptivity has been very encouraging, with the unique data from the SOLOIST trial resonating well with payers and hospital systems [65][87] Question: Can sotagliflozin be commercially successful with a narrow label? - Management is confident in a broad label scenario but believes sotagliflozin can still differentiate and capture market share even with a narrower label [90][101]

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q4 2022 Earnings Conference Call March 2, 2023 5:00 PM ET Company Participants Carrie Siragusa – Executive Director, Corporate Strategy and Investor Relations Lonnel Coats – Chief Executive Officer Jeff Wade – President and Chief Financial Officer Craig Granowitz – Senior Vice President and Chief Medical Officer Conference Call Participants Yasmeen Rahimi – Piper Sandler Carly Kenselaar – Citi Joseph Stringer – Needham & Company Operator Good afternoon, and welcom ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _____________ to _____________ Commission File Number: 000-30111 Lexicon Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 76-0 ...

Financial Data and Key Metrics Changes - The company ended Q3 2022 with $136.2 million in cash and investments, including net proceeds of $94.3 million from a public offering and private placement [29] - Research and development expenses decreased to $10.6 million from $15.7 million in Q3 2021, primarily due to lower external clinical research expenses [32] - Selling, general and administrative expenses increased to $12.6 million from $7.3 million in Q3 2021, mainly due to increased personnel and external expenses related to the commercial launch preparations [33] - The net loss for Q3 2022 was $23.4 million, or $0.13 per share, compared to a net loss of $23.1 million, or $0.16 per share, in Q3 2021 [33] Business Line Data and Key Metrics Changes - The company is actively developing two lead programs: sotagliflozin for heart failure and LX9211 for neuropathic pain [8] - Sotagliflozin is positioned to enter the heart failure market, with a PDUFA target action date anticipated in May 2023 [9] - LX9211 has shown positive top-line results in a Phase II proof-of-concept study for painful diabetic neuropathy, with final data to be presented at an upcoming summit [10][27] Market Data and Key Metrics Changes - Over 6 million people in the U.S. are living with heart failure, with about 1 million new cases diagnosed each year, indicating a large and growing market [11] - Heart failure is the leading cause of hospitalization for Americans over 65, with approximately 1 million hospitalizations annually [12] Company Strategy and Development Direction - The company aims to differentiate sotagliflozin in the heart failure market through unique data from the SOLOIST-WHF trial, which demonstrated significant effects on reducing cardiovascular mortality and hospital readmissions [9][18] - The company is exploring potential partnerships for LX9211 to advance its development and is engaged in discussions to find a strategic fit [26][61] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the upcoming regulatory review for sotagliflozin, noting no significant issues were raised during the mid-cycle review meeting with the FDA [8][37] - The company anticipates launching sotagliflozin in the U.S. in the first half of 2023, contingent on regulatory approval [66] Other Important Information - The company has been granted fast track designation by the FDA for LX9211 in diabetic peripheral neuropathic pain [20] - The final results of the RELIEF-DPN trial will be presented at the 16th Annual Pain Therapeutic Summit, providing further insights into the efficacy of LX9211 [27] Q&A Session Summary Question: Did the FDA request additional data during the mid-cycle review? - Management confirmed that the FDA did not request any new data, indicating a comprehensive submission package [37] Question: Can you elaborate on the potential unique label for sotagliflozin? - Management indicated confidence in obtaining label elements for recent worsening heart failure, as this was the population studied in the SOLOIST trial [39] Question: What differentiates sotagliflozin from other SGLT2 inhibitors? - Management highlighted that other SGLT2 data did not show significant separation until 90 days, while sotagliflozin demonstrated a 52% reduction in all-cause death or heart failure-related events at 90 days [50] Question: What are the plans for LX9211 beyond diabetic neuropathy? - Management noted that preclinical data supports exploring other types of neuropathic pain and potential applications in spasticity [61]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _____________ to _____________ Commission File Number: 000-30111 Lexicon Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) (Sta ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Exact Name of Registrant as Specified in its Charter) (State or Other Jurisdiction of Incorporation or Organization) (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _____________ to _____________ Commission ...